T1	Participants 378 447	a large number of human volunteers in India, Vietnam, and Bangladesh,
T2	Participants 621 696	safety and immunogenicity of the vaccine in 216 healthy adults and children
T3	Participants 801 898	81% adults and 77% children demonstrating seroconversion 14 days after the second dose of vaccine
T4	Participants 982 1005	population outside Asia
